Welcome to the UPF Digital Repository

L1CAM expression in endometrial carcinomas: an ENITEC collaboration study

Show simple item record

dc.contributor.author van der Putten, Louis J.M.
dc.contributor.author Mancebo Moreno, Gemma
dc.contributor.author Alameda Quitllet, Francisco
dc.contributor.author Pijnenborg, Johanna M.A.
dc.date.accessioned 2018-04-20T07:15:26Z
dc.date.available 2018-04-20T07:15:26Z
dc.date.issued 2016
dc.identifier.citation van der Putten LJ, Visser NC, van de Vijver K, Santacana M, Bronsert P, Bulten J.et al. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. Br J Cancer. 2016 Sep 6;115(6):716-24. DOI: 10.1038/bjc.2016.235
dc.identifier.issn 0007-0920
dc.identifier.uri http://hdl.handle.net/10230/34418
dc.description.abstract BACKGROUND: Identification of aggressive endometrioid endometrial carcinomas (EECs) and non-endometrioid carcinomas (NEECs) is essential to improve outcome. L1 cell adhesion molecule (L1CAM) expression is a strong prognostic marker in stage I EECs, but less is known about L1CAM expression in advanced-stage EECs and NEECs. This study analyses L1CAM expression in a clinically representative cohort of endometrial carcinomas. METHODS: The expression of L1CAM was immunohistochemically determined in 1199 endometrial carcinomas, treated at one of the European Network for Individualized Treatment of Endometrial Cancer (ENITEC) centres. Staining was considered positive when >10% of the tumour cells expressed L1CAM. The association between L1CAM expression and several clincopathological characteristics and disease outcome was calculated. RESULTS: In all, L1CAM was expressed in 10% of the 935 stage I EECs, 18% of the 160 advanced stage EECs, and 75% of the 104 NEECs. The expression of L1CAM was associated with advanced stage, nodal involvement, high tumour grade, non-endometrioid histology, lymphovascular space invasion, and distant recurrences in all cases, and with reduced survival in the EECs, but not in the NEECs. CONCLUSIONS: The expression of L1CAM is a strong predictor of poor outcome in EECs, but not NEECs. It is strongly associated with non-endometrioid histology and distant spread, and could improve the postoperative selection of high-risk endometrial carcinomas. The value of L1CAM expression in the preoperative selection of high-risk endometrial carcinomas should be studied
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Nature Publishing Group
dc.rights © Nature Publishing Group. https://www.nature.com/articles/bjc2016235 this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.uri http://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subject.other Tumors -- Mortalitat
dc.subject.other Endometri--Càncer
dc.title L1CAM expression in endometrial carcinomas: an ENITEC collaboration study
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1038/bjc.2016.235
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


In collaboration with Compliant to Partaking